

Zsombor Zrubka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3349691/publications.pdf>

Version: 2024-02-01

44
papers

500
citations

840776

11
h-index

752698

20
g-index

54
all docs

54
docs citations

54
times ranked

537
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. <i>European Journal of Health Economics</i> , 2022, 23, 1243-1255.	2.8	5
2	Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above. <i>European Journal of Health Economics</i> , 2022, 23, 1341-1355.	2.8	7
3	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. <i>Value in Health</i> , 2022, 25, 1590-1601.	0.3	8
4	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. <i>PLoS ONE</i> , 2022, 17, e0264708.	2.5	2
5	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. <i>Pharmacoeconomics</i> , 2022, 40, 587-599.	3.3	9
6	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	3.1	6
7	Risk stratification in endoscopic type I. tympanoplasty. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4757-4766.	1.6	3
8	A biotechnológiai hálónkban. <i>Hungarian Statistical Review</i> , 2021, 99, 512-540.	0.1	1
9	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	2.6	3
10	Outcomes of Digital Biomarker-Based Interventions: Protocol for a Systematic Review of Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e28204.	1.0	17
11	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50-70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	2.8	4
12	State of the Art in Adoption of Contact Tracing Apps and Recommendations Regarding Privacy Protection and Public Health: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23250.	3.7	48
13	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.3	6
14	Costs of Infection Control and Special Challenges during the Covid-19 Pandemic: Experiences in a Military Hospital. <i>Academic and Applied Research in Military and Public</i> , 2021, 20, 95-110.	0.1	1
15	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	1.3	1
16	PP424 Piloting A Comprehensive Search For eHealth Definitions In The Grey Literature: Preliminary Results From A Systematic Scoping Review. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, 36-36.	0.5	9
17	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	2.4	3
18	Thrombocytosis and Effects of IL-6 Knock-Out in a Colitis-Associated Cancer Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6218.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	3.1	13
20	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	3.3	6
21	Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Markers of Survival in Patients with Head and Neck Tumours—Results of a Retrospective Multicentric Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1742.	2.6	21
22	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	4.3	17
23	Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research. <i>Global Journal on Quality and Safety in Healthcare</i> , 2020, 3, 44-54.	0.5	10
24	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	1.4	19
25	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	2.8	6
26	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	2.8	49
27	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	2.8	22
28	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	2.8	12
29	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	2.8	17
30	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	2.8	11
31	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	2.8	8
32	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	2.9	7
33	PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS: SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS. <i>Value in Health</i> , 2018, 21, S288.	0.3	1
34	PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES: EXPLORING A NEW APPLICATION OF THE EQ VAS. <i>Value in Health</i> , 2018, 21, S385.	0.3	0
35	PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L: COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE. <i>Value in Health</i> , 2018, 21, S323.	0.3	1
36	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6770-6778.	1.9	14

#	ARTICLE	IF	CITATIONS
37	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	3.0	9
38	Economic aspects of biosimilar competition in Hungary â€” The treatment of rheumatic disorders. <i>Society and Economy</i> , 2017, 39, 271-290.	0.3	0
39	Applicability Of The EQ-5D-3L Descriptive System To Explore Subjective Future Health Expectations. <i>Value in Health</i> , 2017, 20, A690.	0.3	0
40	Eq-5d Studies In Nervous System Diseases In Eight Central And Eastern European Countries. <i>Value in Health</i> , 2016, 19, A471.	0.3	0
41	EQ-5D Studies in Rheumatology in Eight Central and Eastern European Countries. <i>Value in Health</i> , 2016, 19, A542.	0.3	1
42	EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries. <i>Value in Health</i> , 2016, 19, A657-A658.	0.3	0
43	Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. <i>Current Medical Research and Opinion</i> , 2016, 32, 829-834.	1.9	100
44	A8.31â€¦.Authorised manufacturing changes of therapeutic monoclonal antibodies in EPAR documents. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A94.1-A94.	0.9	2